Full-Time

Cash Accounting Analyst

Posted on 6/14/2025

Agilent Technologies

Agilent Technologies

10,001+ employees

eProcurement solutions for streamlined purchasing

No salary listed

Mid

Bawal, India

Category
Financial Accounting
Management Accounting
Accounting
Required Skills
SAP Products
Excel/Numbers/Sheets
Requirements
  • Commerce graduate
  • Requires higher education or specialized training/certification, or equivalent combination of education and experience
  • 3+ years of experience in finance domain
  • Good accounting knowledge and analytical skills
  • Good Communication skills (written and verbal) & ability to perform multi-tasking and exposure to different cultures
  • Self-driven, positive, flexible towards work, ability to solve problems independently and bring innovative ideas to improve the current process
  • Good collaboration skills
  • Strong proficiency in ERP systems (SAP preferred) & MS excel
Responsibilities
  • Record and reconcile daily cash inflows and outflows, including bank accounts, while collaborating with cross-functional teams to ensure accuracy and alignment
  • Ensure the timely and accurate closure of cash-related GL accounts during the Month-End Close (MEC)
  • Perform monthly reconciliations of cash and bank accounts, while monitoring and effectively managing the aging of balances to ensure accuracy, and timely resolution of outstanding items
  • Ensure adherence to internal control frameworks and company policies related to cash accounting
  • Support audit processes (internal and external) by providing required documentation and explanations
  • Should be a team player and should back up the other team members in times of need.

Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their suite of eProcurement services allows clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system is designed to make it easier for businesses to find and buy the products they need at the right price. Agilent focuses on increasing productivity through automation, faster connectivity, and simplified workflows, which can lead to lower costs and higher profits for their clients. They serve a wide range of customers who value their expertise and reliability, and they generate revenue by offering these eProcurement solutions along with a broad product line.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisitions like Sigsense enhance Agilent's AI capabilities in lab operations.
  • The trend towards paperless transactions boosts Agilent's service efficiency and appeal.
  • Automation in procurement is expected to increase, benefiting Agilent's offerings.

What critics are saying

  • Integration challenges from acquiring BIOVECTRA may disrupt Agilent's operations.
  • Multiple acquisitions could stretch Agilent's resources and management focus.
  • Increased competition from funded companies like RareCyte and Elegen may challenge Agilent.

What makes Agilent Technologies unique

  • Agilent offers a comprehensive suite of eProcurement services for streamlined purchasing.
  • The company focuses on automation and paperless transactions to enhance business productivity.
  • Agilent's hosted catalog and pricing integration simplify procurement processes for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

5%
Business Wire
Jul 30th, 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Biovectra
Jul 22nd, 2024
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care | BIOVECTRA

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...

Finsmes
Jun 27th, 2024
RareCyte Secures $20M Financing

RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding

Business Wire
May 14th, 2024
Elegen Raises $35 Million In Series B To Accelerate Expansion Into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

GenomeWeb
Apr 3rd, 2024
Biofidelity Raises $24M to Expand US Commercialization of Lung Cancer Test, Product Pipeline

The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.